In line with previous evidence, administration of 5‐Aza‐2′‐deoxycytidine (5‐AzadC), a DNA methylation inhibitor, resulted in a reduction of abnormal hypermethylation of the MEG3 promoter and effectively prevented the loss of MEG3 expression in glioma cells. The gene discussed is MEG3; the disease is central nervous system cancer.